TMC
ATRA icon

Trellus Management Company’s Atara Biotherapeutics ATRA Stock Holding History

Trellus Management Company’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,400
Closed -$857K – 58
2022
Q2 		$857K Buy
4,400
+600
+16% +$97.9K 1.04% 17
2022
Q1 		$883K Hold
3,800
– – 0.51% 23
2021
Q4 		$1.5M Sell
3,800
-404
-10% -$170K 1% 20
2021
Q3 		$1.88M Buy
4,204
+1,282
+44% +$459K 1.37% 18
2021
Q2 		$1.14M Buy
2,922
+2,522
+631% +$900K 0.78% 30
2021
Q1 		$144K Sell
400
-476
-54% -$210K 0.07% 62
2020
Q4 		$430K Sell
876
-5,324
-86% -$2.46M 0.35% 48
2020
Q3 		$2.01M Buy
6,200
+200
+3% +$68.1K 2.06% 12
2020
Q2 		$2.19M Buy
6,000
+1,600
+36% +$404K 2.37% 11
2020
Q1 		$936K Buy
4,400
+885
+25% +$281K 1.68% 17
2019
Q4 		$1.45M Buy
3,515
+1,115
+46% +$384K 2.42% 10
2019
Q3 		$847K Buy
2,400
+1,400
+140% +$522K 0.85% 24
2019
Q2 		$503K Buy
+1,000
New +$706K 0.68% 44

Other funds holding ATRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Trellus Management Company's ATRA Position: Q3 2022 in Review

Trellus Management Company sold out of Atara Biotherapeutics (ATRA) in Q3 2022, closing a stake of 4,400 shares — an estimated $857K sold.

Trellus Management Company first reported a position in ATRA in Q2 2019 and held it in 13 quarters. The position peaked at $2.19M in Q2 2020. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

  • Trellus Management Company reported no remaining Atara Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Trellus Management Company sold 4,400 Atara Biotherapeutics shares in Q3 2022, an estimated $857K.
  • Trellus Management Company first reported a position in Atara Biotherapeutics in Q2 2019 and held it in 13 quarters.
  • Trellus Management Company's Atara Biotherapeutics position peaked at $2.19M in Q2 2020.
  • 154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on Trellus Management Company's 13F filing for Q3 2022, filed 25 Oct 2022.